Naluzotan clinical trials
Also written PRX-00023.
How each study uses naluzotan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PRX-00023
- 3
Studies by the year they started
3 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Epix Pharmaceuticals, Inc. (2) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Studies
Open first, then newest update. How each study uses naluzotan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- PRX-00023 Therapy in Localization-Related EpilepsyTerminatedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT01281956Written as PRX-00023
- A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)CompletedPhase 3Epix Pharmaceuticals, Inc.NCT00248183Written as PRX-00023
- A Efficacy Study of PRX-00023 in Patients With Major Depressive DisorderCompletedPhase 2Epix Pharmaceuticals, Inc.NCT00448292Written as PRX-00023
Codes
What other systems call naluzotan · ClinicalTrials.gg INT004935
- MeSH (NLM) C511631naluzotanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LQ54E5B4EWNALUZOTANConfirmed FDA, NLM, Wikidata
- Wikidata Q6961039naluzotanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80775NaluzotanOne source FDA
- DrugBank DB05562One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C511631 | naluzotan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LQ54E5B4EW | NALUZOTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6961039 | naluzotan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80775 | Naluzotan | One source FDA |
| DrugBank | DB05562 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.